Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H28F2O4 |
| Molecular Weight | 394.4521 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
InChI
InChIKey=OGPWIDANBSLJPC-RFPWEZLHSA-N
InChI=1S/C22H28F2O4/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-21(15,3)22(14,24)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1
| Molecular Formula | C22H28F2O4 |
| Molecular Weight | 394.4521 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://web.archive.org/web/20170630002752/http://ca.gsk.com/media/1187415/nerisone.pdfCurator's Comment: description was created based on several sources, including, www.ncbi.nlm.nih.gov/pubmed/23213332
Sources: https://web.archive.org/web/20170630002752/http://ca.gsk.com/media/1187415/nerisone.pdf
Curator's Comment: description was created based on several sources, including, www.ncbi.nlm.nih.gov/pubmed/23213332
Diflucortolone (used in the form of valerate prodrug) is a corticosteroid developed for the treatment of inflammatory skin diseases. It is supposed that Diflucortolone acts by inducing Annexin A1, a phospholipase A2 inhibitory protein, and thus controls the biosynthesis of prostagladins and leukotrienes. The drug is marketed as a cream under the tradename Nerisone.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P04083 Gene ID: 301.0 Gene Symbol: ANXA1 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | NERISONE Approved UseNERISONE® (diflucortolone valerate) preparations are indicated for the topical treatment of corticosteroid-responsive acute and chronic skin diseases, where anti-inflammatory, anti-allergic and anti-pruritic action is required for a maximum duration of 4 weeks. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cutaneous polyarteritis nodosa successfully treated with topical diflucortolone valerate: a case report & review of the literature. | 2014 |
|
| Enhanced dermal delivery of diflucortolone valerate using lecithin/chitosan nanoparticles: in-vitro and in-vivo evaluations. | 2013 |
|
| Congenital infantile digital fibromatosis: a case report and review of the literature. | 2009-12-28 |
|
| Local anti-inflammatory activity and systemic side effects of NM-135, a new prodrug glucocorticoid, in an experimental inflammatory rat model. | 1998-12 |
|
| A test of the half-side comparative design in the clinical evaluation of topical steroids, using diflucortolone and betamethasone creams. | 1985-10 |
|
| [Clinical trial of diflucortolone. Preliminary report]. | 1981 |
|
| [Clinical comparative study of between difluocortolone and flumethasone]. | 1977 |
|
| [Use of diflucortolone in various dermatological processes]. | 1976-10 |
Patents
Sample Use Guides
Apply a thin layer and gently rub in using only enough to cover the affected area once or twice a day for a maximum of 4 weeks.
Route of Administration:
Topical
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:33:27 GMT 2025
by
admin
on
Wed Apr 02 07:33:27 GMT 2025
|
| Record UNII |
K253365DXI
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QD07XC04
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
||
|
WHO-ATC |
D07AC06
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
||
|
WHO-ATC |
D07BC04
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
||
|
WHO-VATC |
QD07AC06
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
||
|
WHO-ATC |
D07XC04
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
||
|
WHO-VATC |
QD07BC04
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
||
|
NCI_THESAURUS |
C521
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID50180705
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
PRIMARY | |||
|
Diflucortolone
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
PRIMARY | |||
|
SUB07128MIG
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
PRIMARY | |||
|
D004060
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
PRIMARY | |||
|
m4432
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL509924
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
PRIMARY | |||
|
11954369
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
PRIMARY | |||
|
220-022-6
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
PRIMARY | |||
|
2395
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
PRIMARY | |||
|
K253365DXI
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
PRIMARY | |||
|
3141
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
PRIMARY | |||
|
C87231
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
PRIMARY | |||
|
100000083157
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
PRIMARY | |||
|
DB09095
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
PRIMARY | |||
|
3392
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
PRIMARY | RxNorm | ||
|
2607-06-9
Created by
admin on Wed Apr 02 07:33:27 GMT 2025 , Edited by admin on Wed Apr 02 07:33:27 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |